PDF(Pubmed)
Abstract：
The objective of this study was to evaluate the utility of urine CD163 for detecting disease activity in childhood-onset SLE (cSLE) patients.
Sixty consecutive pediatric patients fulfilling four or more ACR criteria for SLE and 20 healthy controls were recruited for testing of urinary CD163 using ELISA. SLE disease activity was assessed using the SLEDAI-2K.
Urine CD163 was significantly higher in patients with active LN than inactive SLE patients and healthy controls, with receiver operating characteristics area under the curve values ranging from 0.93 to 0.96. LN was ascertained by kidney biopsy. Levels of CD163 significantly correlated with the SLEDAI, renal SLEDAI, urinary protein excretion and C3 complement levels. Urine CD163 was also associated with high renal pathology activity index and chronicity index, correlating strongly with interstitial inflammation and interstitial fibrosis based on the examination of concurrent kidney biopsies.
Urine CD163 emerges as a promising marker for identifying cSLE patients with active kidney disease. Longitudinal studies are warranted to validate the clinical utility of urine CD163 in tracking kidney disease activity in children with lupus.
Sixty consecutive pediatric patients fulfilling four or more ACR criteria for SLE and 20 healthy controls were recruited for testing of urinary CD163 using ELISA. SLE disease activity was assessed using the SLEDAI-2K.
Urine CD163 was significantly higher in patients with active LN than inactive SLE patients and healthy controls, with receiver operating characteristics area under the curve values ranging from 0.93 to 0.96. LN was ascertained by kidney biopsy. Levels of CD163 significantly correlated with the SLEDAI, renal SLEDAI, urinary protein excretion and C3 complement levels. Urine CD163 was also associated with high renal pathology activity index and chronicity index, correlating strongly with interstitial inflammation and interstitial fibrosis based on the examination of concurrent kidney biopsies.
Urine CD163 emerges as a promising marker for identifying cSLE patients with active kidney disease. Longitudinal studies are warranted to validate the clinical utility of urine CD163 in tracking kidney disease activity in children with lupus.
摘要：
目的：这项研究的目的是评估尿液CD163在检测儿童发作的系统性红斑狼疮（cSLE）患者疾病活动中的实用性。
方法：招募60名符合SLE≥4ACR标准的连续儿科患者和20名健康对照者，使用酶联免疫吸附测定法检测尿CD163。使用SLEDAI-2000评估SLE疾病活动性。
结果：活动性狼疮性肾炎患者的尿液CD163明显高于非活动性SLE患者和健康对照组，ROCAUC值范围为0.93-0.96。通过肾活检确定狼疮性肾炎。CD163水平与SLEDAI显著相关，肾SLEDAI,尿蛋白排泄，和C3补体水平。尿CD163也与高肾脏病理活动指数和慢性指数有关。基于同时检查肾脏活检，与间质炎症和间质纤维化密切相关。
结论：因此，尿CD163是鉴别cSLE活动性肾脏疾病患者的一个有前景的标记物.有必要进行纵向研究，以验证尿液CD163在追踪狼疮儿童肾脏疾病活动中的临床实用性。
方法：招募60名符合SLE≥4ACR标准的连续儿科患者和20名健康对照者，使用酶联免疫吸附测定法检测尿CD163。使用SLEDAI-2000评估SLE疾病活动性。
结果：活动性狼疮性肾炎患者的尿液CD163明显高于非活动性SLE患者和健康对照组，ROCAUC值范围为0.93-0.96。通过肾活检确定狼疮性肾炎。CD163水平与SLEDAI显著相关，肾SLEDAI,尿蛋白排泄，和C3补体水平。尿CD163也与高肾脏病理活动指数和慢性指数有关。基于同时检查肾脏活检，与间质炎症和间质纤维化密切相关。
结论：因此，尿CD163是鉴别cSLE活动性肾脏疾病患者的一个有前景的标记物.有必要进行纵向研究，以验证尿液CD163在追踪狼疮儿童肾脏疾病活动中的临床实用性。
